ACAD earnings analysis
What we found in ACAD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
ACADIA delivered Q2 net product sales of $308.0 million, up 16.4% year over year, as NUPLAZID reached $183.2 million and DAYBUE reached $124.8 million. Diluted EPS improved to $0.18 from $0.02 in Q1 2026, while operating margin recovered to about 12.3% from negative 1.7% sequentially. Liquidity improved to $956.5 million and six-month operating cash flow reached $134.8 million, although commercial-team investment lifted Q2 SG&A to $160.3 million and the RADIANT Phase 2 readout expected in September-October 2026 remains the principal near-term catalyst and risk.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue accelerated sequentially and year over year
- Q2 net product sales were $308.0 million, up $43.4 million (16.4%) from $264.6 million a year earlier. Revenue also rose from $268 million in Q1 2026 to $307.959 million in Q2 2026.
- Both commercial franchises delivered growth
- NUPLAZID sales increased $14.7 million year over year to $183.2 million, while DAYBUE increased $28.7 million to $124.8 million. DAYBUE accounted for roughly two-thirds of the $43.4 million total quarterly product-sales increase.
- Margins rebounded from Q1 loss
- Gross margin was approximately 90.8%, with cost of product sales of $28.3 million, or approximately 9% of $308.0 million revenue. Operating margin recovered to approximately 12.3% from negative 1.7% in Q1 2026 and was essentially in line with 12.2% in Q2 2025.
- EPS improved sequentially and year over year
- Diluted EPS was $0.18, versus $0.02 in Q1 2026 and $0.16 in Q2 2025. The reported $0.18 also exceeded the supplied consensus estimate of $0.04.
- Liquidity strengthened with higher operating cash flow
- Cash, cash equivalents and investment securities rose $136.8 million to $956.5 million at June 30, 2026 from $819.7 million at December 31, 2025. Six-month operating cash flow increased $50.5 million to $134.8 million.
- Near-term catalysts include RADIANT and EU DAYBU
- Management expects Phase 2 RADIANT topline results for remlifanserin between September and October 2026; FDA granted Fast Track designation for Alzheimer’s disease psychosis in July 2026. CHMP issued a positive DAYBU opinion in June 2026, although European Commission authorization remains outstanding.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Commercial investment drove sharply higher SG&A
- Selling, general and administrative expense rose $26.8 million year over year to $160.3 million in Q2, outpacing the $3.6 million increase in R&D to $81.6 million. Management attributes the SG&A increase to expanded U.S. DAYBUE and NUPLAZID teams, creating an ongoing operating-expense execution risk.
- Tariffs could pressure supply costs and margins
- A newly expanded tariff/trade-policy risk notes that DAYBUE API requires approximately two years to produce and that tariff-driven costs may be difficult or impossible to pass through to customers until calendar 2027 at the earliest. The company has substantial reliance on foreign manufacturers, including China.
- Medicare negotiation may pressure NUPLAZID pricing
- The updated reimbursement risk states that 2029 is the earliest year NUPLAZID could face Medicare price negotiation, assuming the company qualifies for the small-biotech exception through 2027. If selected in 2029, management expects a negotiated-price reduction, albeit with a discount phase-in during 2029 and 2030.
- European DAYBU approval and reimbursement remain uncertain
- EU commercialization is not assured despite CHMP's positive June 2026 recommendation following its March 2026 negative opinion. DAYBU still requires European Commission marketing authorization, and national reimbursement outcomes could further delay or limit revenue.
- RADIANT readout carries material pipeline risk
- Clinical-development risk remains material ahead of the Phase 2 RADIANT readout expected between September and October 2026. The filing cites three prior program setbacks: ADVANCE-2 in March 2024, the pediatric autism Phase 2 trial in October 2024, and COMPASS PWS in September 2025.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.18
- Gross margin
- 90.8%
- Operating margin
- 12.3%
- Segment
- NUPLAZID net product sales: $183.2 million, up $14.7 million year over year from $168.5 million.
- Segment
- DAYBUE net product sales: $124.8 million, up $28.7 million year over year from $96.1 million.
What they said about what is next.
The 10-Q does not provide a quantitative revenue or EPS outlook; outlook is deferred to other company communications. Management says cash, cash equivalents and investment securities plus anticipated product sales are expected to fund planned operations through and beyond the next 12 months.
The filing reads better than the one before it.
What came before.
- 10-Q · May 6, 2026
- Acadia Pharmaceuticals reported a disappointing Q1 2026 performance, with revenues of $268.1 million, falling short of the anticipated $280.6 million. EPS also missed expectations, coming in at $0.02 versus the expected…
- 10-K · February 26, 2026
- Acadia reports product sales growth driven by its two commercial franchises: NUPLAZID and DAYBUE, with net product sales from those products of $1,071.5 million in 2025 versus $957.8 million in 2024. Management…
- 10-Q · November 6, 2025
- Acadia reported Q3 product sales of $278,633,000, up 11.3% year-over-year, driven by NUPLAZID and DAYBUE. Diluted EPS was $0.42 (vs. $0.20 prior year) and operating margin improved to 12.8% as income from operations…
- 10-K · February 28, 2024
- Acadia positions itself as a commercial-stage CNS and rare-disease biotech with two approved products: NUPLAZID (approved April 2016) for Parkinson’s disease psychosis and DAYBUE (approved March 2023; launched April…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ACAD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever